Introduction {#s1}
============

Mitochondrial membrane fission and fusion is essential for generating a dynamic mitochondrial network and regenerative partitioning of damaged components via mitophagy ([@bib27]). Membrane rearrangement is essential for organelle function ([@bib13]; [@bib14]) and contributes to diversity in mitochondrial membrane shape that can reflect metabolic and physiological specialization ([@bib41]; [@bib52]; [@bib3]).

Mitochondrial membrane fusion in metazoans is catalyzed by the mitofusins (Mfn1/2) and Opa1 (the outer and inner membrane fusogens, respectively), which are members of the dynamin family of large GTPases ([@bib12]; [@bib2]) ([Figure 1A](#fig1){ref-type="fig"}). An important series of in vitro studies with purified mitochondria showed that outer- and inner membrane fusion can be functionally decoupled ([@bib37]; [@bib36]). Outer membrane fusion requires Mfn1/2, while inner-membrane fusion requires Opa1. Loss of Opa1 function results in a fragmented mitochondrial network, loss of mitochondrial DNA, and loss of respiratory function ([@bib35]; [@bib43]). Opa1 is the most commonly mutated gene in Dominant Optic Atrophy, a devastating pediatric condition resulting in degeneration of retinal ganglion cells. Mutations in Opa1 account for over a third of the identified cases of this form of childhood blindness ([@bib44]).

![An in vitro assay for mitochondrial inner-membrane fusion.\
(**A**) Mitochondrial membrane fusion involves sequential outer and inner membrane fusion. The mitofusins (Mfn1/2) catalyze outer membrane fusion. In metazoans, mitochondrial inner-membrane fusion is mediated by Opa1. (**B**) Linear domain arrangement of l-Opa1. (**C**) Schema of the experimental setup. (**D**) Fusion assay. Membrane tethering, docking, lipid mixing, and content release can be distinguished using fluorescent reporters that specifically reflect each transition of the reaction.](elife-50973-fig1){#fig1}

Like dynamin, Opa1 comprises a GTPase domain, helical bundle signaling element (BSE), and stalk region (with a membrane-interaction insertion) ([Figure 1B](#fig1){ref-type="fig"}) ([@bib48]; [@bib46]; [@bib21]). A recent crystal structure of the yeast orthologue of Opa1, Mgm1, revealed this membrane-interaction insertion is a 'paddle', which contains a series of hydrophobic residues that can dip into one leaflet of a membrane bilayer ([@bib20]).

Opa1 is unique for a dynamin family GTPase, because it is processed to generate two forms. The unprocessed, N-terminal transmembrane anchored, long form is called l-Opa1. The proteolytically processed short form, which lacks the transmembrane anchor, is called s-Opa1 ([@bib39]). Opa1 is processed by two proteases in a region N-terminal to the GTPase domain. Oma1 activity is stimulated by membrane depolarization ([@bib19]). Yme1L activity is coupled to respiratory state. Both forms of the protein (s-Opa1 and l-Opa1) can interact with cardiolipin, a negatively charged lipid enriched in the mitochondrial inner membrane. Opa1 GTPase activity is stimulated by association with cardiolipin ([@bib7]).

Recent structural studies of Mgm1 focused on a short form, s-Mgm1 construct ([@bib21]). This analysis revealed a series of self-assembly interfaces in Mgm1's stalk region. One set of interactions mediates a crystallographic dimer, and a second set, observed in both the crystal and cryo-electron tomographic (cryo-ET) reconstructions, bridge dimers in helical arrays on membrane tubes with both positive and negative curvature. The s-Mgm1 membrane tubes that formed with negative curvature are especially intriguing, because of Opa1's recognized role in cristae regulation, and the correspondence of the in vitro tube topology with cristae inner-membrane invaginations ([@bib37]; [@bib23]). These self-assembled states were not mediated by GTPase-domain dimers.

Integrative biophysical and structural insights have revealed how dynamin nucleotide-state is coupled to GTPase-domain dimerization, stalk-mediated self-assembly and membrane rearrangement ([@bib20]; [@bib22]; [@bib4]; [@bib11]). For Opa1, the opposite reaction (fusion) is also likely to result from nucleotide-dependent conformational changes, coupled domain rearrangement, and self-assembly necessary to overcome the kinetic barriers of membrane merger. Recent crystal structure and electron cryo-tomography reconstructions reveal self-assembly interfaces, and conformational changes that rearrange cristae membranes ([@bib21]). The specific fusogenic nucleotide hydrolysis-driven conformational changes remain to be distinguished.

Classic studies of Mgm1, the yeast orthologue of Opa1, show that both long and short forms are required for inner-membrane fusion ([@bib17]; [@bib26]). Studies by David Chan's group, using mammalian cells, also showed that both long and short forms of Opa1 are required ([@bib50]), and that knock-down of the Opa1 processing protease Yme1L results in a more fragmented mitochondrial network ([@bib39]). Since Yme1L activity is tied to respiratory state, supplying cells with substrates for oxidative phosphorylation shifts the mitochondrial network to a more tubular state. Importantly, Chan and colleagues cleanly demonstrate, with an in vitro purified mitochondria system using protease inhibitors and an engineered cleavage site that mitochondrial fusion is dependent on proteolytic processing ([@bib39]). In contrast, work from the Langer group showed l-Opa1 alone was sufficient for fusion when expressed in a YME1L -/-, OMA1 - /- background ([@bib3]), indicating that Opa1 processing is dispensable for fusion. Over-expression of s-Opa1 in this background resulted in mitochondrial fragmentation, which was interpreted as a result of s-Opa1 mediated fission. Is proteolytic processing of Opa1 required for regulating fusion? Is s-Opa1 required for fusion?

In this study, we applied a TIRF-based supported bilayer/liposome assay ([Figure 1C](#fig1){ref-type="fig"}), to distinguish the sequential steps in membrane fusion that convert two apposed membranes into one continuous bilayer: tethering, membrane docking, lipid mixing (hemifusion) and content release ([Figure 1D](#fig1){ref-type="fig"}). This format allows control of protein levels for all components introduced into the system. Previous in vitro reconstitution studies from Ishihara and colleagues ([@bib8]) were performed in bulk. The analysis we present here resolves individual fusion events in the TIRF field and is more sensitive than bulk measurements. In addition, our assay records kinetic data lost in ensemble averaging. Finally, the assay as applied here, can distinguish stages of fusion for individual liposomes. Tethering is observed when liposomes attach to the supported bilayer. Lipid mixing (hemifusion) is reported when a liposome dye (TexasRed) diffuses into the supported bilayer. Release of a soluble content dye (calcein) from within the liposome (loaded at quenched concentrations) indicates full pore opening. Our assay includes a content reporter dye in all conditions, so we can relate each intermediate with full fusion, for example, comparing instances where there may be lipid mixing, but no content release.

Using this in vitro reconstitution approach, we describe key mechanistic requirements for mitochondrial inner-membrane fusion. We report efficiency and kinetics for each step in Opa1-mediated fusion. These experiments describe the membrane activities of l-Opa1 alone, s-Opa1 alone, and l-Opa1:s-Opa1 together. We find that s-Opa1 and l-Opa1 are both required for efficient and fast pore opening, and present a mechanism for how the ratio of l-Opa1 and s-Opa1 levels regulate inner-membrane fusion. These results are compatible and expand the original yeast observations ([@bib17]), explain previous cellular studies ([@bib3]; [@bib39]), and contextualizes recent in vitro observations ([@bib8]). The data presented here unambiguously describe the activities of Opa1, contributing to a more complete model for how inner-membrane fusion is regulated.

Results {#s2}
=======

Assay validation {#s2-1}
----------------

We purified long and short forms of human Opa1 expressed in *Pichia pastoris*. Briefly, Opa1 was extracted from membranes using n-dodecyl-β-D-maltopyranoside (DDM) and purified by Ni-NTA and Strep-tactin affinity chromatography, and size exclusion chromatography ([Figure 2A](#fig2){ref-type="fig"}). A series of short isoforms are observed in vivo ([@bib35]; [@bib16]). In this study, we focused on a short form corresponding to the S1 isoform resulting from Oma1 cleavage ([Figure 2B](#fig2){ref-type="fig"}). GTPase activity of purified Opa1 was confirmed by monitoring free phosphate release ([Figure 2C and D](#fig2){ref-type="fig"}). Opa1 activity was enhanced by the presence of cardiolipin, consistent with previous reports ([Figure 2C and D](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) ([@bib7]).

![Reconstitution of l-Opa1.\
(**A**) Representative size-exclusion chromatograph and SDS-PAGE gel of human l-Opa1 purified from *P. pastoris.* (**B**) SDS-PAGE gel of human s-Opa1 purified from *P. pastoris*. l-Opa1 activity, with velocity (**C**) and specific activity (**D**) of GTP hydrolysis in the presence and absence of cardiolipin, while varying protein concentration of Opa1. Data are shown as mean ± SD, with error bars from three independent experiments. Representative single-liposome photobleaching steps (**E and F**) and histogram of step sizes (distribution for 110 liposomes shown) (**G**).\
Figure 2---source data 1.Reconstitution of l-Opa1.](elife-50973-fig2){#fig2}

We reconstituted l-Opa1 into 200 nm liposomes and supported bilayers generated by Langmuir-Blodgett/Langmuir-Schaefer methods ([@bib40]). l-Opa1 was added to liposomes and a supported bilayer at an estimated protein:lipid molar ratio of 1:5000 and 1:50000, respectively. Membranes comprised DOPE (20%), Cardiolipin (20%), PI (7%), and DOPC (52.8%). Reporter dyes (e.g. Cy5-PE, TexasRed-PE) were introduced into the supported bilayer and liposome membranes, respectively, at \~0.2% (mol). A surfactant mixture stabilized the protein sample during incorporation. Excess detergent was removed using Bio-Beads and dialysis. We confirmed successful reconstitution by testing the stability of l-Opa1 incorporation under high salt and sodium carbonate conditions, and contrasting these results with s-Opa1 peripheral membrane association ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

We evaluated reconstitution of l-Opa1 into both the polymer-tethered supported lipid bilayers and proteoliposomes using two approaches. First, using Fluorescence Correlation Spectroscopy (FCS), we measured the diffusion of dye-conjugated lipids and antibody-labeled protein. FCS intensity measurements confirmed \~75% of l-Opa1 reconstituted into the bilayer in the accessible orientation. Bilayer lipid diffusion was measured as 1.46 ± 0.12 µm^2^/s, while the diffusion coefficient of bilayer-reconstituted l-Opa1 was 0.88 ± 0.10 µm^2^/s ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}), which is in agreement with previous reports of lipid and reconstituted transmembrane protein diffusion ([@bib49]). These measurements indicate the reconstituted l-Opa1 in the bilayer can freely diffuse, and has the potential to self-associate and oligomerize. Blue native polyacrylamide gel electrophoresis (BN-PAGE) analysis also show the potential for the purified material to self-assemble ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). FCS experiments were also performed on liposomes. FCS intensity measurements confirmed 86.7% of total introduced l-Opa1 successfully reconstituted into the liposomes. The diffusion coefficient of free antibody was 163.87 ± 22.27 µm^2^/s. The diffusion coefficient for liposomes labeled with a lipid dye was 2.22 ± 0.33 µm^2^/s, and the diffusion coefficient for l-Opa1 proteoliposomes bound to a TexasRed labeled anti-His antibody was 2.12 ± 0.36 µm^2^/s ([Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}). Second, we measured the number of l-Opa1 incorporated into liposomes by fluorescent step-bleaching of single proteoliposomes ([Figure 2E and F](#fig2){ref-type="fig"}). We found an average step number of 2.7 for individual l-Opa1-containing proteoliposomes labeled with TexasRed conjugated anti-His antibody, when tethered to cardiolipin containing lipid bilayers ([Figure 2G](#fig2){ref-type="fig"}).

Nucleotide-dependent bilayer tethering and docking {#s2-2}
--------------------------------------------------

Using the supported bilayer/liposome assay sketched in [Figure 1C](#fig1){ref-type="fig"}, we found that l-Opa1 tethers liposomes in a homotypic fashion ([Figure 3A](#fig3){ref-type="fig"}), as reported by the appearance of TexasRed puncta in the TIRF field above a l-Opa1-containing bilayer. This interaction occurred in the absence of nucleotide (apo, nucleotide-free) but was enhanced by GTP. We next investigated requirements for Opa1 tethering. In the absence of cardiolipin, addition of GTP did not change the number of tethered particles under otherwise identical conditions ([Figure 3B](#fig3){ref-type="fig"}). In contrast, with cardiolipin-containing liposomes and bilayers, homotypic l-Opa1:l-Opa1 tethering is enhanced by GTP. Non-hydrolyzable analogues (GMPPCP) disrupt tethering ([Figure 3C](#fig3){ref-type="fig"}), and a hydrolysis-dead mutant (G300E) l-Opa1 shows little tethering ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}), supporting a role for the hydrolysis transition-state in tethering, as observed for atlastin ([@bib34]; [@bib42]). Bulk light scattering measurements of liposome size distributions (by NTA Nanosight) show l-Opa1-mediated liposome clustering requires the presence of GTP ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). These bulk measurements show a GTP-dependent increase in observed particle size.

![The number of liposomes tethered on the planar bilayers in a homotypic format (l-Opa1 on both bilayers) increases in the presence of GTP, when both bilayers contain cardiolipin.\
(**A**) Representative images of liposomes tethered on lipid bilayer (both containing cardiolipin) before (apo, or nucleotide free) and after GTP addition. Scale bar: 5 µm. (**B**) Bar graph: In the presence of cardiolipin, addition of GTP doubles the number of liposomes. (\*\*\*p\<0.001, two way ANOVA). (**C**) Addition of GMPPCP decreases amount of tethered l-Opa1 liposomes (apo, indicating nucleotide free) (p\<0.005, two-way ANOVA). (**D**) l-Opa1 in the liposome bilayer alone is sufficient to tether liposomes to a cardiolipin containing bilayer. Tethering is enhanced in the presence of GTP (apo, indicating nucleotide free) (p\<0.005, two-way ANOVA). (**E**) s-Opa1 tethers liposomes to a cardiolipin-containing bilayer. Number of tethered liposomes when both bilayer and liposomes contain 20% (mol) cardiolipin. Before addition of GTP (apo, indicating nucleotide-free), a moderate amount of liposome tethering was observed. The addition of GTP enhances this tethering effect (p\<0.005, two-way ANOVA). Data are shown as mean ± SD. Error bars are from five independent experiments (\>10 images across one bilayer per for each experiment).\
Figure 3---source data 1.Tethering.](elife-50973-fig3){#fig3}

Ban, Ishihara and colleagues have observed a heterotypic, fusogenic interaction between l-Opa1 on one bilayer and cardiolipin in the opposing bilayer ([@bib8]). Inspired by this work and our own observations, we considered if a heterotypic interaction between l-Opa1 and cardiolipin on the opposing membrane could contribute to l-Opa1-mediated tethering ([Figure 3D](#fig3){ref-type="fig"}). Indeed, we find that proteoliposomes containing l-Opa1 will tether to a cardiolipin-containing bilayer lacking any protein binding partner, presumably mediated by the lipid-binding 'paddle' insertion in the helical stalk region ([@bib21]). This tethering is cardiolipin-dependent, as l-Opa1 containing bilayers do not tether DOPC liposomes ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}).

We next measured whether s-Opa1, lacking the transmembrane anchor, could tether membranes via membrane binding interactions that bridge the two bilayers. We observe that s-Opa1 (added at a protein:lipid molar ratio of 1:5000) can tether cardiolipin liposomes to a cardiolipin-containing planar bilayer, as observed previously for Mgm1 ([@bib1]). Further, this s-Opa1 tethering is enhanced by the presence of GTP ([Figure 3E](#fig3){ref-type="fig"}). Previous reports observed membrane tubulation at higher concentrations of s-Opa1 (0.2 mg/ml, 1.67 nmol) ([@bib7]). Under the lower s-Opa1 concentrations in our experiments (0.16 µg/ml, 2 × 10^−3^ nmol), the supported bilayer remains intact (before and after GTP addition), and we do not observe any evidence of tubular structures forming in the liposomes or bilayers.

Our experiments indicate that s-Opa1 alone can induce tethering. Is s-Opa1 competent for close docking of membranes? To answer this, we evaluated close bilayer approach using a reporter for when membranes are brought within FRET distances (\~40--60 Å). This FRET signal reports on close membrane docking when a TexasRed conjugated PE is within FRET distance of a Cy5-conjugated PE. We observed a low FRET signal for tethered membranes, when the FRET pair is between two supported bilayers tethered via PEG spacer (average distance between the bilayer centers of \~7 nm) ([@bib38]), compared to a single bilayer containing both of the FRET pair ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). When l-Opa1 is present on both bilayers (homotypic arrangement), or on only one bilayer (heterotypic arrangement), efficient docking occurs in the presence of cardiolipin, as reported by a FRET signal with efficiencies of \~40% ([Figure 4B and C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Efficient homotypic docking requires GTP hydrolysis. GMPPCP prevents homotypic docking of l-Opa1, and abolishes the heterotypic l-Opa1 signal) ([Figure 4A](#fig4){ref-type="fig"}). In contrast, s-Opa1 alone does not bring the two bilayers within FRET distance, consistent with observations for s-Mgm1 tethered bilayers ([Figure 4A](#fig4){ref-type="fig"}) ([@bib1]). The distances between two paddles in the s-Mgm1 dimer is \~120 Å. Tethering mediated by two paddle interactions would be compatible with our observed low FRET signal when s-Opa1 engages two bilayers ([@bib20]).

![Docking.\
(**A**) Homotypic l-Opa1 docks liposomes in a GTP-hydrolysis dependent manner. s-Opa1, alone is insufficient to closely dock liposomes. l-Opa1 in a heterotypic format (on the liposome alone) is competent to closely dock to a bilayer, but this docking is not stimulated by nucleotide. Bar graphs shown as mean ± SD (p\<0.0001, one-way ANOVA). Error bars are from 3 to 5 independent experiments (each experiment with \>150 particles in a given bilayer). (**B**) In the presence of cardiolipin on both bilayers, FRET signal reports on close liposome docking mediated by l-Opa1. Left: Green = Cy5 emission signal upon excitation at 543 (TexasRed excitation). Red = Cy5 emission signal in membrane upon excitation at 633 (Cy5 excitation). Right: Green = TexasRed emission upon excitation at 543 nm (TexasRed excitation). Scale bar: 5 µm.\
Figure 4---source data 1.Docking.](elife-50973-fig4){#fig4}

Hemifusion and pore opening {#s2-3}
---------------------------

We find that l-Opa1, when present on only one bilayer, in a heterotypic format, can mediate close membrane docking ([Figure 4A](#fig4){ref-type="fig"}). To quantify hemifusion (lipid exchange), we measured the fluorescence intensity decay times for the liposome dye (TexasRed) as it diffuses into the bilayer during lipid mixing. Analysis of particle dye diffusion kinetics shows that in this heterotypic format, l-Opa1 can induce hemifusion ([Figure 5A](#fig5){ref-type="fig"}). The hemifusion efficiency (percentage of total particles where the proteoliposome dye diffuses into the supported bilayer) for heterotypic l-Opa1 was \<5% ([Figure 6A](#fig6){ref-type="fig"}). Previously published in vitro bulk liposome-based observations for heterotypic l-Opa1 lipid mixing observed hemifusion efficiencies of 5--10%, despite higher protein copy number per liposome ([@bib8]). We next compared homotypic l-Opa1 catalyzed hemifusion and observed shorter mean dwell times than heterotypic l-Opa1 ([Figure 5B and C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In our assay, we observe homotypic l-Opa1 induces hemifusion more efficiently than heterotypic l-Opa1. We measured a homotypic l-Opa1 hemifusion efficiency of \~15% ([Figure 6A](#fig6){ref-type="fig"}). For comparison, in vitro measurements of viral membrane hemifusion, show efficiencies of \~25--80% ([@bib10]; [@bib30]). This comparison is imperfect, as viral particles have many more copies of their fusion proteins on their membrane surface and viral fusogens do not undergo multiple cycles of nucleotide hydrolysis, like Opa1.

![Hemifusion.\
(**A**) Heterotypic hemifusion. Top panels: time trace of proteo-liposome lipid dye diffusion (TexasRed). Bottom panels: no content release is observed for this particle (calcein signal remains quenched). Scale bar: 1 µm. (**B**) Homotypic hemifusion. Top panels: time trace of liposome lipid dye diffusion (TexasRed). Bottom panels: no content release is observed for this particle (calcein signal remains quenched). Scale bar: 1 µm. (**C**) Representative intensity traces of a control particle not undergoing fusion (black), with heterotypic hemifusion event (solid red), and homotypic hemifusion event (dotted red).\
Figure 5---source data 1.Heterotypic and homotypic hemifusion.](elife-50973-fig5){#fig5}

![Hemifusion and full fusion.\
(**A**) Hemifusion (lipid mixing) and full fusion (content release and pore opening) efficiency for homotypic l-Opa1, heterotypic l-Opa1 and s-Opa1 (p\<0.001, two-way ANOVA). Bar graphs shown as mean ± SD. Error bars are from five different experiments (50--200 particles were analyzed per bilayer in each experiment). B. Full fusion (pore opening) efficiency at different s-Opa1:l-Opa1 ratios. Data are shown as mean ± SD. Error bars are from 4 to 6 experiments (80--150 particles per bilayer in each experiment). The significance of the data was confirmed using one-way ANOVA (Prism 8.3) where p\<0.0001. C. Mean pore opening time in the absence of s-Opa1 and at equimolar s-Opa1. Significance of the difference was confirmed using t-test (Prism 8.3, p\<0.0001). D. Representative hemifusion and pore opening fluorescence time series for homotypic l-Opa1 experiment, in the absence of s-Opa1, top and bottom panels, respectively. Scale bar: 1 µm. E: representative traces of TexasRed (liposome signal) and calcein (content signal) intensity for homotypic l-Opa1 experiment. F. Representative hemifusion and pore opening fluorescence traces for a homotypic l-Opa1 experiment in the presence of equimolar s-Opa1. Scale bar: 1 µm. G: Representative trace of TexasRed (liposome signal) and calcein (content signal) intensity for a homotypic l-Opa1 experiment in the presence of equimolar s-Opa1.\
Figure 6---source data 1.Hemifusion and pore opening.](elife-50973-fig6){#fig6}

Following hemifusion, pore opening is the key step where both leaflets merge and content from the two compartments can mix. We observed pore opening by monitoring content dye (calcein) release under these conditions ([@bib47]). Of all homotypic tethered particles,\~18% undergo hemifusion. Of these particles undergoing hemifusion, approximately half proceed to full fusion (8% of all homotypic tethered particles). Both s-Opa1 alone (at 0.16 µg/ml, or 2 × 10^−3^ nmol concentration), or l-Opa1 in the heterotypic format did not release content ([Figure 6A](#fig6){ref-type="fig"}). In contrast,\~8% of homotypic l-Opa1:l-Opa1 particles undergo pore opening and content release. These observations indicate, l-Opa1 alone is sufficient for pore opening, while s-Opa1 alone or heterotypic l-Opa1 are insufficient for full fusion.

Ratio of s-Opa1:l-Opa1 regulate pore opening efficiency and kinetics {#s2-4}
--------------------------------------------------------------------

Our observation that l-Opa1 is sufficient for pore opening leaves open the role of s-Opa1 for fusion. Previous studies suggest an active role for s-Mgm1 (the yeast orthologue of s-Opa1) in fusion ([@bib17]). In this work, l-Mgm1 GTPase activity was dispensable for fusion in the presence of wild-type s-Mgm1 ([@bib17]). Work in mammalian cells suggests different roles for s-Opa1. Studies from the Chan group showed Opa1 processing helps promote a tubular mitochondrial network ([@bib39]). In contrast, other studies showed upregulated Opa1 processing in damaged or unhealthy mitochondria, resulting in accumulation of s-Opa1 and fragmented mitochondria ([@bib39]; [@bib8]; [@bib25]). The interpretation of the latter experiments was that, in contrast to the yeast observations, s-Opa1 suppresses fusion activity. Furthermore, studies using Opa1 mutations that abolish processing of l-Opa1 to s-Opa1 suggest the short form is dispensable for fusion, and s-Opa1 may even mediate fission ([@bib32]; [@bib6]). These different, and at times opposing, interpretations of experimental observations have been difficult to reconcile.

To address how s-Opa1 and l-Opa1 cooperate, we added s-Opa1 to the l-Opa1 homotypic supported bilayer/liposome fusion experiment. l-Opa1-only homotypic fusion has an average dwell time of 20 s and an efficiency of \~10% ([Figure 6B--E](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Upon addition of s-Opa1, we observe a marked increase in pore opening efficiency, reaching 80% at equimolar l-Opa1 and s-Opa1 ([Figure 6B](#fig6){ref-type="fig"}). At equimolar levels of s-Opa1, we also observe a marked change in pore opening kinetics, with a four-fold decrease in mean dwell time ([Figure 6C](#fig6){ref-type="fig"}). The efficiency peaks at an equimolar ratio of s-Opa1 to l-Opa1, showing that s-Opa1 cooperates with l-Opa1 to catalyze fast and efficient fusion. When s-Opa1 levels exceed l-Opa1 (at a 2:1 ratio or greater), particles begin to detach, effectively reducing fusion efficiency. This is consistent with a dominant negative effect, where s-Opa1 likely disrupts the homotypic l-Opa1:l-Opa1 interaction. We quantified particle untethering, and observe a dose-dependent detachment of l-Opa1:l-Opa1 tethered particles with the addition of G300E s-Opa1 ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}).

Discussion {#s3}
==========

Our experiments suggest different assembled forms of Opa1 represent functional intermediates along the membrane fusion reaction coordinate, each of which can be a checkpoint for membrane fusion and remodeling. We show that s-Opa1 alone is sufficient to mediate membrane tethering but is unable to dock and merge lipids in the two bilayers, and thus, insufficient for hemifusion ([Figure 7A](#fig7){ref-type="fig"}). In contrast, l-Opa1, in a heterotypic format, can tether and hemifuse bilayers, but is unable to transition through the final step of pore opening ([Figure 7B](#fig7){ref-type="fig"}). Homotypic l-Opa1 can hemifuse membranes and mediate low levels of pore opening ([Figure 7C](#fig7){ref-type="fig"} i.). However, our results show that s-Opa1 and l-Opa1 together, synergistically catalyze efficient and fast membrane pore opening ([Figure 7C](#fig7){ref-type="fig"} ii.). Importantly, we find that excess levels of s-Opa1 are inhibitory for pore opening, providing a means to down-regulate fusion activity ([Figure 7C](#fig7){ref-type="fig"} iii.).

![Summary model for modes of regulation in Opal-mediated membrane fusion.\
(**A**) s-Opa1 alone is capable of tethering bilayers, but insufficient for close membrane docking and hemifusion. (**B**) l-Opa1, in a heterotypic arrangement, can tether bilayers, and upon GTP stimulation promote low levels of lipid mixing, but no full fusion, pore opening or content release. (**C**) Homotypic l-Opa1-l-Opa1 tethered bilayers can mediate full content release (i). This activity is greatly stimulated by the presence of s-Opa1, with peak activity at 1:1 s-Opa1:l-Opa1 (ii). Excess levels of s-Opa1 suppress fusion, likely through competing with the l-Opa1-l-Opa1 homotypic tethering interface (iii).](elife-50973-fig7){#fig7}

Our model proposes that l-Opa1:s-Opa1 stoichiometry gates the final step of fusion, pore opening. Electron tomography studies of mitofusin show a unevenly distributed ring of proteins clustering at an extensive site of close membrane docking, but only local regions of pore formation ([@bib9]). Our study is consistent with local regions of contact and low protein copy number mediating lipid mixing and pore formation ([@bib54]). Our study would predict that s-Opa1 enrichment in regions of the mitochondrial inner-membrane would suppress fusion. This study did not explore the roles of s-Opa1 assemblies (helical or 2-dimensional) in fusion ([@bib21]). Cellular validation of our proposed model, and other states, will require correlating l-Opa1:s-Opa1 ratio and protein spatial distribution with fusion efficiency and kinetics. This study focused on isoform 1 of l-Opa1 and the S1 form of s-Opa1. The behavior of other Opa1 splice isoforms, which vary in the processing region, remains another important area for future investigation ([@bib51]).

The results and model presented here help resolve the apparent contradicting nature of the Chan and Langer cellular observations. As observed by the Langer group, l-Opa1 alone in our system, is indeed sufficient for full fusion, albeit at very low levels ([@bib3]). The activity of unprocessed Opa1 was not ruled out in previous studies of Chan and colleagues ([@bib39]). In contrast to the Langer group's conclusions, we find that s-Opa1 strongly stimulates l-Opa1-dependent fusion activity, independent of the Yme1L processing reaction ([@bib39]). Under conditions of s-Opa1 overexpression, Langer et al. observed, a fragmented mitochondrial network. We do not see any evidence for fission or fusion, for s-Opa1 alone, under our reconstitution conditions. Instead, our data and model suggest this is due to s-Opa1 disrupting l-Opa1 activity, swinging the membrane dynamics equilibrium toward fission.

Mitochondrial dysfunction is often associated with Opa1 processing ([@bib18]). The activity of the mitochondrial inner-membrane proteases, Yme1L and Oma1, is regulated by mitochondrial matrix state, thereby coupling organelle health to fusion activity ([@bib3]; [@bib6]; [@bib18]; [@bib45]; [@bib29]). Basal levels of Opa1 cleavage are observed in healthy cells ([@bib39]). Upon respiratory chain collapse and membrane depolarization increased protease activity elevates s-Opa1 levels, downregulating fusion ([@bib5]). Our results point to the importance of basal Opa1 processing, and are consistent with observations that both over-processing and under-processing of l-Opa1 can result in a loss of function ([@bib3]).

Key questions remain in understanding the function of different Opa1 conformational states, and the nature of a fusogenic Opa1 complex. Recent structural studies show s-Mgm1 self-assembles via interfaces in the stalk region ([@bib21]; [@bib53]). The nucleotide-independent tethering we observe also implicate stalk region interactions, outside of a GTPase-domain dimer, in membrane tethering. How does nucleotide hydrolysis influence these interactions during fusion? Outstanding questions also remain in understanding the cooperative interplay between local membrane environment, s-Opa1, and l-Opa1. Could the cooperative activity of l-Opa1 and s-Opa1 be mediated by direct protein-protein interactions, local membrane change, or both? Could tethered states (e.g. homotypic l-Opa1 or heterotypic l-Opa1) bridge bilayers to support membrane spacings seen in cristae? Answers to these questions, and others, await further mechanistic dissection to relate protein conformational state, in situ architecture and physiological regulation.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\   Designation                                                                                             Source or reference                         Identifiers                                                     Additional\
  or resource                                                                                                                                                                                                                                   information
  ------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------------------
  Chemical compound, drug   18:1 (Δ9-Cis) PC (DOPC)                                                                                 Avanti Polar lipids                         Cat \#: 850375P                                                 

  Chemical compound, drug   1\',3\'-bis\[1,2-dioleoyl-sn-glycero-3-phospho\]-glycerol (sodium salt)                                 Avanti Polar lipids                         Cat \#: 710335P                                                 

  Chemical compound, drug   1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-\[methoxy(polyethylene glycol)−2000\] (ammonium salt)   Avanti Polar lipids                         Cat \#: 880130P                                                 

  Chemical compound, drug   L-α-lysophosphatidylinositol (Liver, Bovine) (sodium salt)                                              Avanti Polar lipids                         Cat \#: 850091P                                                 

  Chemical compound, drug   1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine                                                   Avanti Polar lipids                         Cat \#: 850757P                                                 

  Chemical compound, drug   Texas Red 1,2-Dihexadecanoyl-sn-Glycero-3-Phosphoethanolamine, Triethylammonium Salt (Texas Red DHPE)   ThermoFisher Scientific                     Cat \#: T1395MP                                                 

  Chemical compound, drug   1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(Cyanine 5)                                             Avanti polar lipid                          Cat \#: 810335C1mg                                              

  Chemical compound, drug   Calcein                                                                                                 Sigma-Aldrich                               Cat \#: C0875; PubChem Substance ID: 24892279                   

  Strain                    *Pichia pastoris* SMD1163 (*his4,pep, prb1*)                                                            Rapoport lab; Harvard Medical School.                                                                       

  Recombinant DNA reagent   pPICZ A-TwinStrep-lOPA1-H~10~                                                                           GenScript                                                                                                   plasmid to transform and express human WT l-Opa1 (isoform1).

  Recombinant DNA reagent   pPICZ A-TwinStrep-sOPA1-H~10~                                                                           GenScript                                                                                                   plasmid to transform and express human WT s-Opa1 (s1).

  Recombinant DNA reagent   pPICZ A-TwinStrep-lOPA1 (G300E)-H~10~                                                                   GenScript                                                                                                   plasmid to transform and express G300E mutant of l-Opa1 (isoform 1).

  Recombinant DNA reagent   pPICZ A-TwinStrep-sOPA1 (G300E)-H~10~                                                                   GenScript                                                                                                   plasmid to transform and express G300E mutant of s-Opa1 (s1).

  Antibody                  Rabbit Anti-Opa1 antibody                                                                               NOVUS BIOLOGICALS                           Cat \#: NBP2-59770                                              Western Blot 2 ug/ml

  Antibody                  Mouse 6x-His Tag Monoclonal Antibody (HIS.H8)                                                           ThermoFisher Scientific                     Cat \#: MA1-21315                                               Western Blot 1:2000

  Antibody                  Mouse StrepMAB-Classic, HRP conjugate (2-1509-001)                                                      IBA Lifesciences                            Cat \#: 2-1509-001                                              Western Blot 1:2500/1:32000

  Antibody                  Rabbit IgG HRP Linked Whole Ab                                                                          SIGMA-ALDRICH INC                           Cat \#: GENA934-1ML                                             

  Antibody                  Mouse IgG HRP Linked Whole Ab                                                                           SIGMA-ALDRICH INC                           Cat \#: GENA931-1ML                                             

  Chemical compound, drug   GTP Disodium salt                                                                                       SIGMA-ALDRICH INC                           Cat \#: 10106399001                                             

  Commercial assay, kit     EnzChek Phosphate Assay Kit                                                                             ThermoFisher Scientific                     Cat \#: E6646                                                   

  Chemical compound, drug   GppCp (Gmppcp), Guanosine-5\'-\[(β,γ)-methyleno\]triphosphate, Sodium salt                              Jena Bioscience                             Cat \#: NU-402--5                                               

  Chemical compound, drug   n-Dodecyl-β-D-Maltopyranoside                                                                           Anatrace                                    Cat \#: D310 25 GM                                              

  Chemical compound, drug   n-Octyl-α-D-Glucopyranoside                                                                             Anatrace                                    Cat \#: O311HA 25 GM                                            

  Chemical compound, drug   Lauryl Maltose Neopentyl Glycol (LMNG)                                                                  Anatrace                                    Cat \#: NG310                                                   

  Chemical compound, drug   LMNG-CHS Pre-made solution                                                                              Anatrace                                    Cat \#: NG310-CH210                                             

  Chemical compound, drug   Zeocin                                                                                                  Invivogen                                   Cat \#: ant-zn-1p                                               

  Chemical compound, drug   Ni-NTA                                                                                                  Biorad                                      Cat \#: 7800812                                                 

  Chemical compound, drug   StrepTactin XT                                                                                          IBA Lifesciences                            Cat \#: 2-4026-001                                              

  Chemical compound, drug   Biotin                                                                                                  IBA Lifesciences                            Cat \#: 2-1016-005                                              

  Chemical compound, drug   Superose 6 Increase 10/300 GL                                                                           GE                                          Cat \#: 29091596                                                

  Chemical compound, drug   TEV protease                                                                                            Prepared in lab, purchased from GenScript   Cat \#: Z03030                                                  

  Chemical compound, drug   Benzonase Nuclease                                                                                      Sigma-Aldrich                               Cat \#: E1014                                                   

  Chemical compound, drug   Protease inhibitor cocktail                                                                             Roche                                       Cat \#: 05056489001                                             

  Chemical compound, drug   Leupeptin                                                                                               Sigma-Aldrich                               Cat \#: L2884                                                   

  Chemical compound, drug   Pepstatin A                                                                                             Sigma-Aldrich                               Cat \#: P5318                                                   

  Chemical compound, drug   Benzamidine hydrochloride hydrate                                                                       Sigma-Aldrich                               Cat \#: B6506                                                   

  Chemical compound, drug   Phenylmethylsulfonyl fluoride (PMSF)                                                                    Sigma-Aldrich                               Cat \#: 10837091001                                             

  Chemical compound, drug   Aprotinin                                                                                               Sigma-Aldrich                               Cat \#: A1153                                                   

  Chemical compound, drug   Trypsin inhibitor                                                                                       Sigma-Aldrich                               Cat \#: T9128                                                   

  Chemical compound, drug   Bestatin                                                                                                GoldBio                                     Cat \#: B-915--100                                              

  Chemical compound, drug   E-64                                                                                                    GoldBio                                     Cat \#: E-064--25                                               

  Chemical compound, drug   Phosphoramidon disodium salt                                                                            Sigma-Aldrich                               Cat \#: R7385                                                   

  Commercial assay, kit     3--12% Bis-Tris Protein Gels                                                                            ThermoFisher Scientific                     BN1003BOX                                                       

  Commercial assay, kit     NativePAGE Running Buffer Kit                                                                           ThermoFisher Scientific                     BN2007                                                          

  Commercial assay, kit     NativePAGE 5% G-250 Sample Additive                                                                     ThermoFisher Scientific                     BN2004                                                          

  Commercial assay, kit     NativePAGE Sample Buffer (4X)                                                                           ThermoFisher Scientific                     BN2003                                                          

  Software, algorithm       Slidebook                                                                                               Intelligent imaging                         RRID: [SCR_014300](https://scicrunch.org/resolver/SCR_014300)   

  Software, algorithm       Fiji/ImageJ                                                                                             Fiji                                        SCR_002285                                                      

  Software, algorithm       FCS analysis tool                                                                                       Smith Lab, University of Akron                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Expression and purification {#s4-1}
---------------------------

Genes encoding l- (residues 88--960) or s- (residues 195--960) OPA1 (UniProt O60313-1) were codon optimized for expression in *Pichia pastoris* and synthesized by GenScript (NJ, USA). The sequences encode Twin-Strep-tag, HRV 3C site, (G~4~S)~3~ linker at the N-terminus and (G~4~S)~3~ linker, TEV site, deca-histidine tag at the C-terminus. The plasmids were transformed into the methanol inducible SMD1163 strain (gift from Dr. Tom Rapoport, Harvard Medical School) and the clones exhibiting high Opa1 expression were determined using established protocols. For purification, cells expressing l-Opa1 were resuspended in buffer A (50 mM sodium phosphate, 300 mM NaCl, 1 mM 2-mercaptoethanol, pH 7.5) supplemented with benzonase nuclease and protease inhibitors and lysed using an Avestin EmulsiFlex-C50 high-pressure homogenizer. The membrane fractions were collected by ultracentrifugation at 235,000 x g for 45 min. at 4°C. The pellet was resuspended in buffer A containing 2% DDM, (Anatrace, OH, USA) 0.1 mg/ml 18:1 cardiolipin (Avanti Polar Lipids, AL, USA) and protease inhibitors and stirred at 4°C for 1 hr. The suspension was subjected to ultracentrifugation at 100,000 x g for 1 hr at 4°C. The extract containing l-Opa1 was loaded onto a Ni-NTA column (Biorad, CA, USA), washed with 40 column volumes of buffer B (50 mM sodium phosphate, 350 mM NaCl, 1 mM 2-mercaptoethanol, 1 mM DDM, 0.025 mg/ml 18:1 cardiolipin, pH 7.5) containing 25 mM imidazole and 60 column volumes of buffer B containing 100 mM imidazole. The bound protein was eluted with buffer B containing 500 mM imidazole, buffer exchanged into buffer C (100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM 2-mercaptoethanol, 0.15 mM DDM, 0.025 mg/ml 18:1 cardiolipin, pH 8.0). In all the functional assays, the C-terminal His tag was cleaved by treatment with TEV protease and passed over the Ni-NTA and Strep-Tactin XT Superflow (IBA Life Sciences, Göttingen, Germany) columns attached in tandem. The Strep-Tactin XT column was detached, washed with buffer C and eluted with buffer C containing 50 mM biotin. The elution fractions were concentrated and subjected to size exclusion chromatography in buffer D (25 mM BIS-TRIS propane, 100 mM NaCl, 1 mM TCEP, 0.025 mg/ml 18:1 cardiolipin, pH 7.5, 0.01% LMNG, 0.001% CHS). s-OPA1 was purified using a similar approach but with one difference: post lysis, the DDM was added to the unclarified lysate at 0.5% concentration and stirred for 30 min. -- 1 hr. at 4°C prior to ultracentrifugation. The supernatant was applied directly to the Ni-NTA column.

GTPase activity assay {#s4-2}
---------------------

The GTPase activity of purified Opa1 was analyzed using EnzCheck Phosphate Assay Kit (Thermo Fisher, USA) according to the vendor's protocol. Each condition was performed in triplicate. The GTPase assay buffers contained 25 mM HEPES, 60 mM NaCl, 100 mM KCl, 0.5 mM MgCl~2~ with 0.15 mM DDM. 60 µM GTP was added immediately before data collection. To compare the effect of cardiolipin on GTPase activity, additional 0.5 mg/ml Cardiolipin was dissolved in the reaction buffer and added to the reaction to a final concentration of 0.02 mg/ml. The absorbance at 340 nm of each reaction mixture was recorded using SpectraMax i3 plate reader (Molecular Devices) every 30 s. Experiments were performed in triplicate. Resulting Pi concentration was fitted to a single-phase exponential-decay, specific activity data were fitted to a Michaelis-Menten equation (GraphPad Prism 8.1).

Preparation of polymer-tethered lipid bilayers {#s4-3}
----------------------------------------------

Lipid reagents, including 1,2-dioleoyl-sn-glycero-3-phosphocholine, (DOPC); 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-\[methoxy(polyethylene glycol)−2000\] (DOPE-PEG2000), L-α-phosphatidylinositol (Liver PI) and 1\',3\'-bis\[1,2-dioleoyl-sn-glycero-3-phospho\]-glycerol (cardiolipin) were purchased from Avanti Polar Lipids (AL, USA). To fabricate the polymer-tethered lipid bilayers, we combined Langmuir-Blodgett and Langmuir-Schaefer techniques, using a Langmuir-Blodgett Trough (KSV-NIMA, NY, USA) ([@bib49]; [@bib24]). For cardiolipin-free lipid bilayers, a lipid mixture with DOPC with 5% (mol) DOPE-PEG2000% and 0.2% (mol) Cy5-DSPE at the total concentration of 1 mg/ml was spread on the air water interface in a Langmuir trough. The surface pressure was kept at 30 mN/m for 30 min before dipping. The first lipid monolayer was transferred to the glass substrate (25 mm diameter glass cover slide, Fisher Scientific, USA) through Langmuir-Blodgett dipping, where the dipper was moved up at a speed of 22.5 mm/min. The second leaflet of the bilayer was assembled through Langmuir-Schaefer transfer after 1 mg/ml of DOPC with 0.2% (mol) Cy5-PE (Avanti Polar Lipids, AL, USA) was applied to an air-water interface and kept at a surface pressure of 30 mN/m.

Lipid bilayer with cardiolipin was fabricated in a similar manner, where the bottom leaflet included 7% (mol) Liver PI, 20% (mol) cardiolipin, 20% (mol) DOPE, 5% (mol) DOPE-PEG2000, 0.2% (mol) Cy5-PE and 47.8% DOPC. The composition of the top leaflet of the bilayer was identical except for the absence of DOPE-PEG2000. To match the area/molecule at the air-water interface between CL-free and CL-containing bilayer, the film pressure was kept at 37 mN/m. The final average area per lipid, which is the key factor affecting lipid lateral mobility, was kept constant at a A~lipid~ = 65 Å^2^ ([@bib33]).

Double bilayers were fabricated according to previous reports ([@bib38]). The first bilayer containing DOPC with 5% (mol) DSPE-PEG2000-Maleimide (Avanti Polar Lipids, AL, USA) and 0.2% (mol) Cy5-DOPE in both inner and outer leaflets was made using Langmuir-Blodgett/Langmuir-Schaefer methods. The second planar lipid bilayer was formed by fusion of lipid vesicles and removal of non-fused vesicles. Lipid vesicles were formed by hydrating dried lipid films with DOPC, 0.2% (mol) TexasRed-DHPE and 5% (mol) of linker lipid (DPTE, AL, USA) in a 0.1 mM sucrose/1 mM CaCl~2~ solution. The lipid suspension was heated for 1.5 hr at 75°C, and added to the first bilayer in a 0.1 mM glucose/1 mM CaCl~2~ solution. After 2 hr of incubation, additional vesicles were removed by extensive rinsing. The bilayer was then imaged by TIRF microscope.

Reconstitution of l-Opa1 into lipid bilayers {#s4-4}
--------------------------------------------

Purified l-Opa1 was first desalted into 25 mM Bis-Tris buffer with 150 mM NaCl containing 1.2 nM DDM and 0.4 µg/L of cardiolipin to remove extra surfactant during purification. The resulting protein was added to each bilayer to the total amount of 1.3 × 10^−12^ mol (protein:lipid 1:10000) together with a surfactant mixture of 1.2 nM of DDM and 1.1 nM n-Octyl-β-D-Glucopyranoside (OG, Anatrace, OH, USA). The protein was incubated for 2 hr before removal of the surfactant. To remove the surfactant, Bio-Beads SM2 (Bio-Rad, CA, USA) was added to the solution at a final concentration of 10 µg beads per mL of solution and incubated for 10 min. Buffer with 25 mM Bis-Tris and 150 mM NaCl was applied to remove the Bio-beads with extensive washing. Successful reconstitution was determined using fluorescent correlation spectroscopy assay as described in the supplemental materials.

Preparation of liposomes and proteoliposomes {#s4-5}
--------------------------------------------

To prepare calcein (MilliporeSigma, MA, USA) encapsulated liposomes, lipid mixtures (7% (mol) PI, 20% cardiolipin, 20% PE, 0.2% TexasRed-PE, DOPC (52.8%)), were dissolved in chloroform and dried under argon flow for 25 min. The resulting lipid membrane was mixed in 25 mM Bis-Tris with 150 mM NaCl and 50 mM calcein through vigorous vortexing. Lipid membranes were further hydrated by incubating the mixtures under 70°C for 30 min. Large unilamellar vesicles (LUVs) were prepared by extrusion (15 to 20 times) using a mini-extruder with 200 nm polycarbonate membrane.

Proteoliposomes were prepared by adding purified l-Opa1 in 0.1 µM DDM to prepared liposomes at a protein: lipid of 1:5000 (2.5 µg l-Opa1 for 0.2 mg liposome) and incubated for 2 hr. Surfactant was removed by dialysis overnight under 4°C using a 3.5 KDa dialysis cassette. Excess calcein was removed using a PD-10 desalting column. The final concentration of liposome was determined by TexasRed absorbance, measured in a SpectraMax i3 plate reader (Molecular Devices).

To evaluate l-Opa1 reconstitution into proteoliposomes, dye free liposome was prepared with TexasRed conjugated anti-His tag Antibody (ThermoFisher) by mixing lipids with antibody containing buffer. TexasRed Labeling efficiency of the antibody was calculated to be 1.05 according to the vendor's protocol. Antibodies were added at a concentration of 2.6 µg/ml to 0.2 mg/ml liposome. Following hydration through vortexing at room temperature for 15 min, Large unilamellar vesicles were formed following 20 times extrusion procedure described above. Liposomes labeled with 0.02% (mol) TexasRed-PE were also prepared as a standard for quantifying reconstitution rate.

For the co-flotation analysis, 200 µl of 20 mg/ml TexasRed-DHPE (0.2% (mol)) labeled proteoliposome (reconstitution ratio, protein:lipid 1:5000) was loaded to sucrose gradient (with steps of 0%, 15%, 30%, 60%). The volume of each fraction was 800 µl. Sucrose solutions were prepared in Bis-Tris buffer (25 mM Bis-Tris, 150 mM NaCl, pH 7.4). Samples were then centrifuged using a high-speed centrifuge equipped with SW 55i rotor (Beckmann Coulter, CA, USA) for 2.5 hr at a speed of 30000 xg. For high salt and carbonate treatment, the same amount of proteoliposome was redistributed in Bis-Tris buffer with 500 mM NaCl (pH 7.4) and buffer containing 50 mM Na~2~CO~3~ and 50 mM NaCl (pH 8.2), respectively. The resulting suspension was loaded in gradient for separation. After centrifugation, all fractions were collected and concentrated to 40 µl. Fractions were detected by western blot and then analyzed by ImageJ. The presence of liposomes was detected by absorbance at 590 nm using a DeNovix FX photometer (DeNovix, Inc).

Fluorescent correlation spectroscopy {#s4-6}
------------------------------------

Fluorescence correlation spectroscopy (FCS) was performed using a home-built PIE-FCCS system ([@bib28]; [@bib15]). Two pulsed laser beams with wavelengths of 488 nm (9.7 MHz, five ps) and 561 nm (9.7 MHz, five ps) were filtered out from a supercontinuum white light fiber laser (SuperK NKT Photonics, Birkerod, Denmark) and used as excitation beams. The laser beams were sent through a 100X TIRF objective (NA 1.47, oil, Nikon Corp., Tokyo, Japan) to excite the samples in solution or on bilayer. The emission photons were guided through a common 50 μm diameter pinhole. The light was spectrally separated by a 560 nm high-pass filter (AC254-100-A-ML, Thorlabs), further filtered by respective bandpass filters (green, 520/44 nm \[FF01-520/44-25\]; red, 612/69 nm \[FF01-621/69-25\], Semrock), and finally reach two single photon avalanche diode (SPAD) detectors (Micro Photon Devices). The synchronized photon data were collected using a time correlated single photon counting (TCSPC) module (PicoHarp 300, PicoQuant, Berlin, Germany).

The collected photon data were transformed into correlation functions with a home written MATLAB code. The correlation functions were fitted using two-dimensional ([@bib27]) or three-dimensional ([@bib13]) Brownian diffusion model for bilayer or solution samples respectively.$$G\left( \tau \right) = \frac{1}{\left\langle N \right\rangle}\frac{1}{1 + \frac{\tau}{\tau_{D}}}$$$$G\left( \tau \right) = \frac{1}{\left\langle N \right\rangle}\frac{1}{1 + \frac{\tau}{\tau_{D}}}\frac{1}{\sqrt{1 + \omega^{2} \bullet \frac{\tau}{\tau_{D}}}}$$

Where N is the average number of particles in the system, $\omega$ is the waist of the excitation beam, and τ~D~ is the dwell time that can be used to calculate the diffusion coefficient (D) of the particles ([@bib28]).$$\tau_{D} = \frac{\omega^{2}}{4D}$$

Measurements were made on buffers with evenly distributed liposomes, proteoliposomes and antibodies in a glass-bottom 96 well plate at room temperature. The plates were pre-coated with lipid bilayer fabricated from 100 nm DOPC liposomes. For each solution, data were collected in five successive 15 s increments.

For characterization of l-Opa1 reconstitution into planar bilayers, an anti-Opa1 C-terminal antibody (Novus Biologicals, CO, USA) was used. The antibody was labeled by TexasRed (Texas Red-X Protein Labeling Kit, ThermoFisher, CA, USA). Labeling efficiency of the antibody was determined as 1.52 TexasRed/antibody, as determined by NanoDrop (ThermoFisher, CA, USA). The labeled antibody was added to l-Opa1 in the supported bilayer at twice the total introduced Opa1 concentration. Excess antibody was removed by extensive rinsing.

To estimate reconstitution efficiency, 0.002% (mol) l-Opa1 was added to the bilayer. In a separate experiment 0.002% (mol) TexasRed-PE was introduced to the bilayer. The reconstitution efficiency was calculated from the anti-l-Opa1 antibody TexasRed fluorophore density divided by the TexasRed-PE fluorphore density, normalized by the antibody labeling efficiency (1.5 dye molecules/antibody).

Total Internal Reflection Fluorescent Microscopy (TIRF) {#s4-7}
-------------------------------------------------------

Liposome docking and lipid exchange events were imaged using a Vector TIRF system (Intelligent Imaging Innovations, Inc, Denver, CO, USA) equipped with a W-view Gemini system (Hamamatsu photonics, Bridgewater, NJ). TIRF images were acquired using a 100X oil immersion objective (Ziess, N.A 1.4). A 543 nm laser was used for the analysis of TexasRed-PE embedded liposomes and proteoliposomes, while a 633 nm laser was applied for the analysis of Cy5-PE embedded in the planar lipid bilayer. Fluorescent emission was simultaneously observed through a 609-emission filter with a band width of 40 nm and a 698-emission filter with a band width of 70 nm. The microscope system was equipped with a Prime 95B scientific CMOS camera (Photometrics), maintained at −10°C. Images were taken at room temperature, before adding any liposome or proteoliposome, after 15 mins of addition, and after 30 mins of adding GTP (1 mM) and MgCl~2~ (1 mM). Each data point was acquired from five different bilayers, each bilayer data contains 5--10 particles on average.

Dwell times for hemifused particles were recorded from the moment of GTP addition for pre-tethered particles, until the time of half-maximal TexasRed signal decay. Full fusion events were recorded by monitoring the calcein channel at particle locations identified through the TexasRed signal. Particle identification and localization used both uTrack ([@bib31]) and Slidebook (Intelligent Imaging Innovations, Inc, Denver, CO) built-in algorithms. To calibrate the point spread function 100 nm and 50 nm fluorescent particles (ThermoFisher Scientific) were used. 2D Gaussian detection was applied in both cases. 2-way ANOVA tests were done using GraphPad Prism. Intensity and distribution of the particles were analyzed using ImageJ.

For analysis of protein reconstitution in proteoliposome (stoichiometry), a TIRF microscope modified from an inverted microscope (Nikon Eclipse Ti, Nikon Instruments) was used. A 561 nm diode laser (OBIS, Coherent Inc, Santa Clara, USA) was applied at TIRF angle through a 100X TIRF objective (NA 1.47, oil, Nikon) and the fluorescence signals were collected by an EMCCD camera (Evolve 512, Photometrics).

Nanosight NTA analysis {#s4-8}
----------------------

A NTA300 Nanosight instrument was used to evaluate size distribution of liposome and proteoliposome under different conditions. The equipment was equipped with a 405 nm laser and a CMOS camera. 1 ml of 0.1 µg/ml sample was measured, to reach the recommended particle number of 1 × 10^8^ particles/mL (corresponding to the dilution factor of 1:100,000). Image acquisition was conducted for 40 s for each acquisition and repeated for 10 times for every injection. Three parallel samples were examined for the determination of size distribution. Under each run, the camera level was set to 12 and the detection threshold was set at 3.

Blue native polyacrylamide gel electrophoresis (BN-PAGE) {#s4-9}
--------------------------------------------------------

Bis-Tris gradient gels (3--12%) were purchased from ThermoFisher Scientific (Cat. No. BN1003BOX) and BN-PAGE was performed according to manufacturer's instructions. Gel samples (10 μl) were prepared by mixing indicated quantity of Opa1 with sample buffer containing 0.25% Coomassie G-250 and 1 mM DDM. For experiments involving l-Opa1 and s-Opa1 mixtures, the samples were incubated on ice for 10 min before loading. The cathode buffer contained 1 mM DDM and electrophoresis was performed at 4°C with an ice jacket surrounding the apparatus.
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**Acceptance summary:**

The work presented addresses the molecular mechanism of inner membrane fusion mediated by the mammalian dynamin related GTPase, Opa1. The experiments use a reconstituted in vitro fusion system that distinguishes between the key steps in membrane fusion: tethering, membrane docking, lipid mixing (hemifusion), and content mixing. Among the key findings are that both l-Opa1 and s-Opa1 are required for efficient fusion.

**Decision letter after peer review:**

Thank you for submitting your article \"Two forms of Opa1 cooperate to complete fusion of the mitochondrial inner-membrane\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Axel Brunger as the Reviewing Editor and Suzanne Pfeffer as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The work presented addresses the molecular mechanism of inner membrane fusion mediated by the mammalian dynamin related GTPase, Opa1. The experiments use a reconstituted in vitro fusion system that distinguishes between the key steps in membrane fusion: tethering, membrane docking, lipid mixing (hemifusion), and content mixing. Among the key findings are that both l-Opa1 and s-Opa1 are required for efficient fusion. While the findings are of considerable interest, some additional control experiments interrogating reconstituted l- and s-Opa1 isoforms are required. In addition, the results should be better related to the other results in the literature.

Major revisions:

Control experiments assessing the fidelity of reconstitution are required, for example, is l-Opa1 integral or peripherally associated with membranes? Is it salt/carbonate resistant? This is critical given peripheral l-Opa1 likely will function like s-Opa1 both by its intrinsic GTPase activities/assembly properties and by exchanging between membranes. This control would strengthen the validity of all of the conclusions derived from l-Opa1 reconstitution experiments: homotypic tethering, heterotypic-CL tethering, rations of L-Opa1/s-Opa1, etc.

Previous work (both in vitro and in vitro) suggested that membrane integrated l-Mgm1 possesses no GTPase activity and that GTPase activity is not required for fusion, respectively. These previous results are now contradicted by the data presented in Figure 2. As control, please address the role of GTPase activity in s-Opa1 and l-Opa1 for tethering and fusion using mutant proteins that interfere with GTPase activity.

Please comment why in Figure 3 tethering is observed even in the absence of GTP and Cardiolipin, which are both described to be necessary for Opa1 membrane fusion. In Figure 3B when incubated with nonhydrolyzable GTP analog one can see much lower tethering than in basal (apo) state. Is Opa1 able to tether liposomes by its own?

Based on Figure 2---figure supplement 3, the authors claim that Opa1 has the potential to self-associate and oligomerize in their reconstituted system. Please perform blue native page (BN PAGE) to verify oligomerization and association.

s-Opa1 tethering in Figure 3D and no FRET in the same situation in Figure 4 is puzzling. If s-Opa1 causes tethering and membranes must be within 40Å for FRET, then the complex of s-Opa1 must be bigger or there is already hemifusion as shown in Figure 5, which is causing the FRET to work. Is there any possible \"proof of principle\" experiment, which would show FRET in tethered liposomes without hemifusion? Please perform BN PAGE of l-Opa1 and s-Opa1 to verify if s-Opa1 is not inducing some bigger protein complexes. Electron microscopy to show different tethering of l-Opa1 and s-Opa1 would be desirable, but not essential.

In the last result section, high concentrations of s-Opa1 inhibit fusion by disruption of the l-Opa1:l-Opa1 interaction. Please perform BN-PAGE with increasing concentration of s-Opa1 to see if s-Opa1 really binds to the complex l-Opa dimers.

Textual revisions:

The Introduction and Discussion are inadequate in terms of presenting an overview of the existing knowledge regarding Opa1 mechanism and function. At a minimum, the Introduction should include recent structural work on Mgm1 published by the Daumke group and present functional work from the Langer and Chan labs on the roles of long and short Opa1 isoforms. Indeed, the primary contribution of the work is providing definitive evidence that both Opa1 isoforms are required for fusion, which directly refutes observations in cells from the Langer lab that l-Opa1 is sufficient for fusion. This point should be discussed in detail. There is much debate in the field as to the requirements of s and l forms of Opa1 in fusion. The Chan lab also has data indicating that Opa1 processing is coupled to and required for fusion. In addition, work in yeast showed that the long isoform stimulated the GTPase activity of the short isoform. The justification statement in the Introduction that the \"...activities of the two forms and their regulator interplay remain unclear\" is not accurate.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Two forms of Opa1 cooperate to complete fusion of the mitochondrial inner-membrane\" for further consideration by *eLife*. Your revised article has been evaluated by Suzanne Pfeffer (Senior Editor) and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed In the final revision before acceptance, as outlined below.

Reviewer \#1:

The manuscript is greatly improved. Many of the technical concerns have now been addressed. In terms of assessing GTPase requirements of l- and s-Opa1, did the authors test G300E l-Opa1 with wt s-Opa1 for membrane tethering and fusion activity? This requested experiment is not apparently presented and was one of the key experiments requested i.e. what is the role of the l-GTPase domain?

The addition of relevant previous findings from the Langer and Chan groups also improved the manuscript. However, the language used regarding the key finding of the Chan group -- that OPA1 processing per se is required for fusion -- is not accurately described. The authors must clarify between the requirement for s-OPA1 versus l-OPA1 processing to s-OPA1 for fusion. Please see below for the passages/edits that need to be revised for accuracy on this point.

Perhaps the origin for this confusion comes from the following statement:

"Since Yme1L activity is tied to respiratory state, supplying cells with substrates for oxidative phosphorylation shifts the mitochondrial network to a more tubular state. These observations led the Chan group to conclude that Opa1 processing is important for fusion."

This statement is not entirely correct. In vitro analysis of mitochondrial fusion using protease inhibitors etc indicated that processing per se was required for fusion.

"These directly conflicting interpretations of cellular observations have remained unreconciled. Is proteolytic processing of Opa1 required for regulating fusion, and if so, is the processing stimulatory or inhibitory?"

Suggested revision: Is proteolytic processing of Opa1 required for regulating fusion? Is s-Opa1 required for fusion?

"Our model proposes that l-Opa1:s-Opa1 stoichiometry, resulting from proteolytic processing, gates the final step of fusion, pore opening."

Suggested revision: Our model proposes that l-Opa1:s-Opa1 stoichiometry gates the final step of fusion, pore opening.

"In contrast to the Langer group\'s conclusions, we find that Opa1 processing strongly stimulates fusion activity, as observed by the Chan and colleagues."

Suggested revision: In contrast to Chan\'s conclusions, we find that s-Opa1 strongly stimulates l-Opa1 dependent fusion activity independent of the Yme1 processing reaction.

10.7554/eLife.50973.sa2

Author response

> Major revisions:
>
> Control experiments assessing the fidelity of reconstitution are required, for example, is l-Opa1 integral or peripherally associated with membranes? Is it salt/carbonate resistant? This is critical given peripheral l-Opa1 likely will function like s-Opa1 both by its intrinsic GTPase activities/assembly properties and by exchanging between membranes. This control would strengthen the validity of all of the conclusions derived from l-Opa1 reconstitution experiments: homotypic tethering, heterotypic-CL tethering, rations of L-Opa1/s-Opa1, etc.

We thank the reviewers for suggesting this important control, and now include data showing that l-Opa1 reconstituted into cardiolipin-containing liposomes is indeed salt and carbonate-resistant (Figure 2---figure supplement 2A-C). We show that l-Opa1 reconstituted into cardiolipin-free (DOPC) liposomes show similar salt and carbonate-resistant behavior (Figure 2---figure supplement 2D-F), indicating reconstitution is not dependent on cardiolipin in the liposomes. Finally, we show s-Opa1 membrane liposome association is dependent on the presence of cardiolipin, as s-Opa1 co-floats with cardiolipin liposomes (Figure 2---figure supplement 2G), but does not co-float with DOPC liposomes (Figure 2---figure supplement 2J). High salt treatment did not show a dramatic effect on the s-Opa1 cadiolipin interaction (Figure 2---figure supplement 2H), consistent with a hydrophobic, rather than electrostatic, interaction by the membrane 'paddle'-mediated association. However, carbonate treatment disrupts s-Opa1 association with cardiolipin liposomes (Figure 2---figure supplement 2I). These control observations are consistent with successful reconstitution of l-Opa1 into liposomes, and peripheral membrane association of s-Opa1, which together support the use of l-Opa1 proteoliposomes for this study.

> Previous work (both in vitro and in vitro) suggested that membrane integrated l-Mgm1 possesses no GTPase activity and that GTPase activity is not required for fusion, respectively. These previous results are now contradicted by the data presented in Figure 2. As control, please address the role of GTPase activity in s-Opa1 and l-Opa1 for tethering and fusion using mutant proteins that interfere with GTPase activity.

The material used in Figure 2 was solubilized in DDM during purification, and the GTPase activity reported is for detergent-solubilized material. Detergent-solubilized WT l-Opa1 material shows activity dependent on the presence of cardiolipin (Figure 2C and D). We have now added additional experimental data showing the GTPase activity for WT s-Opa1, G300E l-Opa1, and G300E s-Opa1 (Figure 2---figure supplement 1A-D). We note that detergent-solubilized material is free from membrane constraints, and these regulatory interactions due to association with the membrane may be lost. Attempts to measure GTPase activity of our liposome-reconstituted material in the EnzCheck Phosphate Assay assays were unsuccessful due to background from the liposomes.

We performed an additional set of experiments testing the role of GTPase activity on tethering. WT l-Opa1 tethering is disrupted by the presence of G300E s-Opa1 (Figure 3---figure supplement 1A). Increasing amounts of G300E s-Opa1 results in l-Opa1 tethered liposomes detaching from the l-Opa1-containing bilayer. As previously observed, the hydrolysis-dead mutant G300E l-Opa1 alone does not tether liposomes to a supported bilayer (Figure 3---figure supplement 1B). Also, G300E l-Opa1 in the presence of equimolar amounts of G300E s-Opa1 does not induce membrane tethering (Figure 3---figure supplement 1B).

We also investigated the potential for l-Opa1 to potentiate the activity of s-Opa1. Using detergent solubilized material, we did not see dramatic enhancement of s-Opa1 activity in the presence of G300E l-Opa1 (Figure 2---figure supplement 1F). There is also little effect for WT l-Opa1 activity in the presence of G300E s-Opa1 (Figure 2---figure supplement 1E). It is worth noting that we use a different GTPase-dead mutant from the S224A mutant used in previous studies (DeVay et al., 2009) that showed l-Opa1 potentiation of s-Opa1.

> Please comment why in Figure 3 tethering is observed even in the absence of GTP and Cardiolipin, which are both described to be necessary for Opa1 membrane fusion. In Figure 3B when incubated with nonhydrolyzable GTP analog one can see much lower tethering than in basal (apo) state. Is Opa1 able to tether liposomes by its own?

Our experiments implicate interactions outside of the GTP-ase domains for tethering. These interactions may include one of the stalk interfaces observed by Faelber et al. The accessibility of these interfaces, may be dependent on nucleotide state. Since tethering is an obligate step for fusion, under these conditions, we do not observe any hemifusion or pore opening events. We find that l-Opa1 does not tether naked liposomes lacking l-Opa1 or cardiolipin, indicating l-Opa1 alone is unable to tether liposomes. This observation also indicates the tethering effects we observe are not due to defects induced by reconstitution that could cause liposomes to stick to an exposed glass regions (Figure 4---figure supplement 1B).

> Based on Figure 2---figure supplement 3, the authors claim that Opa1 has the potential to self-associate and oligomerize in their reconstituted system. Please perform blue native page (BN PAGE) to verify oligomerization and association.

We now include BN-PAGE of the proteins used in this study (Figure 2---figure supplement 4A). Both l-Opa1 and s-Opa1 run as an oligomeric mixture, with a major species slightly above and below \~480KDa, respectively. For this detergent solubilized material, the orientation relative to the bilayer may be an important factor influencing self-assembly. These observations support the claim that the proteins have the potential to self-associate. We observe that these proteins freely diffuse (at much lower concentrations) in the membranes, as observed by FCS.

> s-Opa1 tethering in Figure 3D and no FRET in the same situation in Figure 4 is puzzling. If s-Opa1 causes tethering and membranes must be within 40Å for FRET, then the complex of s-Opa1 must be bigger or there is already hemifusion as shown in Figure 5, which is causing the FRET to work. Is there any possible \"proof of principle\" experiment, which would show FRET in tethered liposomes without hemifusion?

We have now included a "proof of principle\" experiment comparing FRET signals for intra-bilayer FRET and inter-bilayer FRET (signal between two supported lipid bilayers tethered by PEG), in the absence of hemifusion (Figure 4---figure supplement 1A). Under our imaging conditions and microscope settings, we observe low FRET for membranes tethered with a distance of \~7 nm, in contrast with high levels of intra-bilayer FRET. Both homotypic and heterotypic arrangements of l-Opa1 are capable of inducing moderate (\~40%) levels of FRET between bilayers. Bilayers tethered by s-Opa1 alone show low levels of FRET. Recent crystal structures of s-Mgm1 from Faelber et al. show the distances of the paddle domains to be \~120 Å. A dimer bridging two bilayers in this arrangement would be expected to have low FRET signal.

> Please perform BN PAGE of l-Opa1 and s-Opa1 to verify if s-Opa1 is not inducing some bigger protein complexes. Electron microscopy to show different tethering of l-Opa1 and s-Opa1 would be desirable, but not essential.

As noted, BN-PAGE of s-Opa1 and l-Opa1 show major species slightly above and below \~480KDa, respectively (Figure 2---figure supplement 4A). The size of this assembly (consistent with a tetramer), may allow for tethering interactions in the absence of FRET (discussed above). Electron microscopy analysis of l-Opa1 and s-Opa1 tethering complexes on liposomes is an important next step, but outside the scope of this study.

> In the last result section, high concentrations of s-Opa1 inhibit fusion by disruption of the l-Opa1:l-Opa1 interaction. Please perform BN-PAGE with increasing concentration of s-Opa1 to see if s-Opa1 really binds to the complex l-Opa dimers.

We note that a strength of the supported bilayer system is the ability to orient molecules in a manner expected at a site of membrane-membrane contact. Our competition experiments show that the tethered state can be competed for with G300E s-Opa1 (Figure 3---figure supplement 1A). We also performed the BN-PAGE titration (increasing the concentration of s-Opa1, in the presence of l-Opa1 as suggested), but found results inconclusive (Figure 2---figure supplement 4B). Addition of s-Opa1 to l-Opa1 results in a mixture of species from \~480 KDa to 1 MDa. This pattern is also seen with G300E l-Opa1 + WT s-Opa1. We are not able to distinguish the composition of the higher order species (whether there is both s-Opa1 and l-Opa1), because they were purified with the same tags, but note that in the presence of excess G300E s-Opa1, there is a slight enrichment of a \~700 KDa species in the presence of l-Opa1. The range of oligomeric species seen in the BN-PAGE gels is consistent with larger oligomers forming at high protein concentrations. Since BN-PAGE of detergent solubilized material will release the constraints of the membrane, we cannot specifically distinguish whether a tethered state is disrupted using this method.

> Textual revisions:
>
> The Introduction and Discussion are inadequate in terms of presenting an overview of the existing knowledge regarding Opa1 mechanism and function. At a minimum, the Introduction should include recent structural work on Mgm1 published by the Daumke group and present functional work from the Langer and Chan labs on the roles of long and short Opa1 isoforms. Indeed, the primary contribution of the work is providing definitive evidence that both Opa1 isoforms are required for fusion, which directly refutes observations in cells from the Langer lab that l-Opa1 is sufficient for fusion. This point should be discussed in detail. There is much debate in the field as to the requirements of s and l forms of Opa1 in fusion. The Chan lab also has data indicating that Opa1 processing is coupled to and required for fusion. In addition, work in yeast showed that the long isoform stimulated the GTPase activity of the short isoform. The justification statement in the Introduction that the \"...activities of the two forms and their regulator interplay remain unclear\" is not accurate.

We have removed the justification statement and revised the Introduction to highlight important recent structural work from the Daumke group. The previous functional work from the Chan and Langer labs is now discussed in detail in both the Introduction and Discussion, as to relate it with this study. We thank the reviewers for the chance to better place this study in context with previous work.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> Reviewer \#1:
>
> The manuscript is greatly improved. Many of the technical concerns have now been addressed. In terms of assessing GTPase requirements of l- and s-Opa1, did the authors test G300E l-Opa1 with wt s-Opa1 for membrane tethering and fusion activity? This requested experiment is not apparently presented and was one of the key experiments requested ie what is the role of the l-GTPase domain?

We assessed the GTPase activity for G300E l-Opa1 with WT s-Opa1 in our previous revision. In Figure 2---figure supplement 1 we measured the GTPase activity of G300E l-Opa1 with WT s-Opa1 and found the specific activity to be similar to WT-s-Opa1 alone, suggesting the l-Opa1 GTPase domain is not stimulating activity of the s-Opa1 GTPase domain. As we noted in our previous response, this mixture of l-Opa1 and s-Opa1 is different from previous comparisons (DeVay et al., 2009), because of the different mutant used (S224A), and the fact that we measured the activity of detergent solubilized material.

In this new revision, we include data for G300E l-Opa1 membrane tethering in the presence of WT s-Opa1, in a new Figure 3---figure supplement 1, panel C. We apologize for the omission. We find that G300E l-Opa1 alone does not tether liposomes, as previously described Figure 3---figure supplement 1, panel B. As we add WT s-Opa1 to G300E l-Opa1 we do see an increased number of liposomes tethered to the supported bilayer. At 1:1 G300E l-Opa1:WT s-Opa1, we do not see any full fusion events. We note, however, that s-Opa1 alone tethers liposomes to a supported bilayer (Figure 3E), so we cannot exclude that these liposomes are interacting through s-Opa1 only, nor can distinguish from this experiment which liposomes are tethering via a G300E l-Opa1:WT s-Opa1 heterocomplex. In order to address these questions, we require independently labeled variants of the two forms, so that we can relate tethering and fusion with the composition of proteins present. This line of experiments is of great interest to us, but outside the scope of this study.

> The addition of relevant previous findings from the Langer and Chan groups also improved the manuscript. However, the language used regarding the key finding of the Chan group -- that OPA1 processing per se is required for fusion -- is not accurately described. The authors must clarify between the requirement for s-OPA1 versus l-OPA1 processing to s-OPA1 for fusion. Please see below for the passages/edits that need to be revised for accuracy on this point.

We thank the reviewer for emphasizing this point and worked to ensure the manuscript clearly articulates this important past finding. We edited the language, in all passages indicated, to clarify and distinguish between the requirement for s-Opa1, versus l-Opa1 processing to s-Opa1 for fusion.

> Perhaps the origin for this confusion comes from the following statement:
>
> "Since Yme1L activity is tied to respiratory state, supplying cells with substrates for oxidative phosphorylation shifts the mitochondrial network to a more tubular state. These observations led the Chan group to conclude that Opa1 processing is important for fusion."
>
> This statement is not entirely correct. In vitro analysis of mitochondrial fusion using protease inhibitors etc indicated that processing per se was required for fusion.

This statement is now modified, and reads: Since Yme1L activity is tied to respiratory state, supplying cells with substrates for oxidative phosphorylation shifts the mitochondrial network to a more tubular state. Importantly, Chan and colleagues cleanly demonstrate, with an in vitro purified mitochondria system using protease inhibitors and an engineered cleavage site that mitochondrial fusion is dependent on proteolytic processing.

> "These directly conflicting interpretations of cellular observations have remained unreconciled. Is proteolytic processing of Opa1 required for regulating fusion, and if so, is the processing stimulatory or inhibitory?"
>
> Suggested revision: Is proteolytic processing of Opa1 required for regulating fusion? Is s-Opa1 required for fusion?

Done.

> "Our model proposes that l-Opa1:s-Opa1 stoichiometry, resulting from proteolytic processing, gates the final step of fusion, pore opening."
>
> Suggested revision: Our model proposes that l-Opa1:s-Opa1 stoichiometry gates the final step of fusion, pore opening.

Done.

> "In contrast to the Langer group\'s conclusions, we find that Opa1 processing strongly stimulates fusion activity, as observed by the Chan and colleagues."
>
> Suggested revision: In contrast to Chan\'s conclusions, we find that s-Opa1 strongly stimulates l-Opa1 dependent fusion activity independent of the Yme1 processing reaction.

Done.

[^1]: Rammelkamp Center for Research and Department of Medicine, MetroHealth System; Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Ohio, United States.
